Celera Acquires Interest in HuBit Genomix
By Labmedica staff writers
Posted on 30 Mar 2001
An agreement to acquire a minority interest in Hubit Genomix, Inc. (Tokyo, Japan), an emerging biotechnology company, has been announced by Celera Genomics (Rockville, MD, USA). Financial terms were not disclosed.Posted on 30 Mar 2001
Hubit Genomix is focused on the discovery and association of genes, particularly single nucleotide polymorphisms (SNPs), for use in the development of therapeutics and diagnostics. The company plans to provide its biologic information to pharmaceutical, biotechnology companies, and research centers. Celera, an operating group of Applera Corp., has developed an online information business and other services based on its generation, integration, and analysis of biologic information.
"This agreement represents an important opportunity for both companies, since it should allow HuBit to expand its research and development in analyzing genetic variation, potentially involving Celera as a business and scientific partner in these important areas,” said J. Craig Venter, Ph.D, president and chief scientific officer of Celera.
Related Links:
Celera Genomics
.jpg)
New
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
New
Gold Member
Automatic Hematology Analyzer
CF9600
New
Chromogenic Culture System
InTray™ COLOREX™ ECC
New
Clinical Informatics Platform
CLARION™
